Neutralizing Antibody Levels as a Correlate of Protection Against <scp>SARS‐CoV</scp>‐2 Infection: A Modeling Analysis
Guillaume Lingas(Inserm), Benjamin Terrier(Hôpital Cochin)
Cited by 11
Related Papers
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
|Science|2020|3.2k
Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients*
|British Journal of Dermatology|2021|414
Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey
|Blood|2012|239
Usual interstitial pneumonia in ANCA-associated vasculitis: A poor prognostic factor
|Journal of Autoimmunity|2019|90
VEXAS syndrome is characterized by inflammasome activation and monocyte dysregulation
|Nature Communications|2024|87